NASDAQ:DVAX Dynavax Technologies (DVAX) Stock Forecast, Price & News $11.66 +0.18 (+1.57%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$11.48▼$11.7050-Day Range$9.65▼$11.6652-Week Range$9.42▼$17.48Volume1.07 million shsAverage Volume1.16 million shsMarket Capitalization$1.49 billionP/E Ratio7.47Dividend YieldN/APrice Target$24.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Dynavax Technologies MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside105.8% Upside$24.00 Price TargetShort InterestBearish14.38% of Shares Sold ShortDividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews Sentiment1.42Based on 3 Articles This WeekInsider TradingSelling Shares$190,914 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.56) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector157th out of 983 stocksPharmaceutical Preparations Industry69th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingDynavax Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.00, Dynavax Technologies has a forecasted upside of 105.8% from its current price of $11.66.Amount of Analyst CoverageDynavax Technologies has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.38% of the outstanding shares of Dynavax Technologies have been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.Change versus previous monthShort interest in Dynavax Technologies has recently increased by 1.77%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDynavax Technologies does not currently pay a dividend.Dividend GrowthDynavax Technologies does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDynavax Technologies has received a 74.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Hepatitis B vaccines", "Clinical research services for infectious diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Dynavax Technologies is -1.59. Previous Next 3.0 News and Social Media Coverage News SentimentDynavax Technologies has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Dynavax Technologies this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for DVAX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows4 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dynavax Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $190,914.00 in company stock.Percentage Held by InsidersOnly 2.62% of the stock of Dynavax Technologies is held by insiders.Percentage Held by Institutions94.26% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Dynavax Technologies are expected to grow in the coming year, from ($0.56) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dynavax Technologies is 7.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.97.Price to Earnings Ratio vs. SectorThe P/E ratio of Dynavax Technologies is 7.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.17.Price to Book Value per Share RatioDynavax Technologies has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Dynavax Technologies (NASDAQ:DVAX) StockDynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.Read More Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DVAX Stock News HeadlinesMay 30, 2023 | finance.yahoo.comDynavax to Present at Upcoming Investor ConferencesMay 8, 2023 | finance.yahoo.comDynavax to Present at the JMP Securities Life Sciences ConferenceJune 4, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 5, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Dynavax Technologies Co. Lifted by HC Wainwright (NASDAQ:DVAX)May 5, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Dynavax Technologies Co. (NASDAQ:DVAX) Increased by AnalystMay 5, 2023 | americanbankingnews.comJMP Securities Trims Dynavax Technologies (NASDAQ:DVAX) Target Price to $24.00May 4, 2023 | msn.comJMP Securities Maintains Dynavax Technologies (DVAX) Outperform RecommendationMay 3, 2023 | msn.comHC Wainwright & Co. Reiterates Dynavax Technologies (DVAX) Buy RecommendationJune 4, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 3, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Dynavax TechnologiesMay 3, 2023 | finance.yahoo.comQ1 2023 Dynavax Technologies Corp Earnings CallMay 3, 2023 | seekingalpha.comDynavax Technologies: The Covid Lifeline ExpiresMay 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Dynavax (DVAX) and Axonics Modulation Technologies (AXNX)May 2, 2023 | finance.yahoo.comDynavax Technologies (DVAX) Reports Q1 Loss, Tops Revenue EstimatesMay 2, 2023 | finance.yahoo.comDynavax Technologies (DVAX) Q1 2023 Earnings Call TranscriptMay 2, 2023 | seekingalpha.comDynavax Technologies Corporation (DVAX) Q1 2023 Earnings Call TranscriptMay 2, 2023 | finance.yahoo.comDynavax Reports First Quarter 2023 Financial ResultsMay 1, 2023 | markets.businessinsider.comDynavax Technologies earnings: here's what to expectMay 1, 2023 | americanbankingnews.comDynavax Technologies (DVAX) Scheduled to Post Earnings on TuesdayApril 20, 2023 | benzinga.comDynavax Technologies Stock (NASDAQ:DVAX), DividendsApril 18, 2023 | finance.yahoo.comDynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023April 9, 2023 | finance.yahoo.comDynavax Technologies (NASDAQ:DVAX) delivers shareholders solid 53% CAGR over 3 years, surging 6.4% in the last week aloneMarch 19, 2023 | finance.yahoo.comDynavax Technologies Corporation (NASDAQ:DVAX) Could Be Riskier Than It LooksMarch 1, 2023 | finance.yahoo.comDynavax to Present at the Cowen 43rd Annual Health Care ConferenceMarch 1, 2023 | msn.comDynavax Technologies's Return On Capital Employed InsightsFebruary 28, 2023 | markets.businessinsider.comDynavax Gets Great Britain Marketing Authorization For Hepatitis B Vaccine Heplisav BFebruary 28, 2023 | finance.yahoo.comDynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted VaccineSee More Headlines DVAX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DVAX Company Calendar Last Earnings11/04/2021Today6/03/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:DVAX CUSIP26815810 CIK1029142 Webwww.dynavax.com Phone(510) 848-5100Fax510-848-1327Employees311Year Founded1996Price Target and Rating Average Stock Price Forecast$24.00 High Stock Price Forecast$27.00 Low Stock Price Forecast$21.00 Forecasted Upside/Downside+105.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.56 Trailing P/E Ratio7.47 Forward P/E RatioN/A P/E GrowthN/ANet Income$293.16 million Net Margins35.99% Pretax Margin36.26% Return on Equity45.49% Return on Assets23.65% Debt Debt-to-Equity Ratio0.39 Current Ratio9.07 Quick Ratio8.44 Sales & Book Value Annual Sales$722.68 million Price / Sales2.06 Cash Flow$2.36 per share Price / Cash Flow4.95 Book Value$4.41 per share Price / Book2.64Miscellaneous Outstanding Shares127,700,000Free Float124,354,000Market Cap$1.49 billion OptionableOptionable Beta1.49 Social Links Key ExecutivesRyan SpencerChief Executive Officer & DirectorDavid F. NovackPresident & Chief Operating OfficerKelly MacDonaldChief Financial Officer & Senior Vice PresidentRobert JanssenChief Medical Officer & SVP-Clinical DevelopmentTodd LopemanVice President-Technical OperationsKey CompetitorsIronwood PharmaceuticalsNASDAQ:IRWDLigand PharmaceuticalsNASDAQ:LGNDGeronNASDAQ:GERNMannKindNASDAQ:MNKDOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,534 shares on 5/26/2023Ownership: 0.014%Ameriprise Financial Inc.Sold 22,665 shares on 5/22/2023Ownership: 0.345%JPMorgan Chase & Co.Sold 170,626 shares on 5/18/2023Ownership: 0.166%New York State Common Retirement FundSold 68,205 shares on 5/18/2023Ownership: 0.053%Thrivent Financial for LutheransSold 29,119 shares on 5/17/2023Ownership: 0.241%View All Insider TransactionsView All Institutional Transactions DVAX Stock - Frequently Asked Questions Should I buy or sell Dynavax Technologies stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DVAX shares. View DVAX analyst ratings or view top-rated stocks. What is Dynavax Technologies' stock price forecast for 2023? 3 Wall Street research analysts have issued 12 month price objectives for Dynavax Technologies' stock. Their DVAX share price forecasts range from $21.00 to $27.00. On average, they expect the company's share price to reach $24.00 in the next year. This suggests a possible upside of 105.8% from the stock's current price. View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts. How have DVAX shares performed in 2023? Dynavax Technologies' stock was trading at $10.64 at the start of the year. Since then, DVAX shares have increased by 9.6% and is now trading at $11.66. View the best growth stocks for 2023 here. When is Dynavax Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our DVAX earnings forecast. How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.05 by $0.29. The biopharmaceutical company earned $108.27 million during the quarter, compared to analyst estimates of $77.30 million. Dynavax Technologies had a trailing twelve-month return on equity of 45.49% and a net margin of 35.99%. During the same period last year, the business earned ($0.15) EPS. What ETFs hold Dynavax Technologies' stock? ETFs with the largest weight of Dynavax Technologies (NASDAQ:DVAX) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), ETFMG Treatments Testing and Advancements ETF (GERM), Invesco S&P SmallCap Health Care ETF (PSCH), ETC 6 Meridian Small Cap Equity ETF (SIXS), Invesco S&P SmallCap Quality ETF (XSHQ), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and SPDR S&P Biotech ETF (XBI). What is Eddie Gray's approval rating as Dynavax Technologies' CEO? 13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend. What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA). What is Dynavax Technologies' stock symbol? Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX." Who are Dynavax Technologies' major shareholders? Dynavax Technologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.78%), Federated Hermes Inc. (9.85%), State Street Corp (7.00%), Chicago Capital LLC (4.55%), Bank of America Corp DE (3.40%) and Fisher Asset Management LLC (3.09%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer. View institutional ownership trends. How do I buy shares of Dynavax Technologies? Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Dynavax Technologies' stock price today? One share of DVAX stock can currently be purchased for approximately $11.66. How much money does Dynavax Technologies make? Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.49 billion and generates $722.68 million in revenue each year. The biopharmaceutical company earns $293.16 million in net income (profit) each year or $1.56 on an earnings per share basis. How many employees does Dynavax Technologies have? The company employs 311 workers across the globe. How can I contact Dynavax Technologies? Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for the company is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at ir@dynavax.com, or via fax at 510-848-1327. This page (NASDAQ:DVAX) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.